Nephrotoxicity of acyclovir and cis-diamminedichloroplatinum(II)--effect of co-administration in rats

J Cancer Res Clin Oncol. 1992;118(3):181-6. doi: 10.1007/BF01410131.

Abstract

The effect of co-administration of acyclovir and cis-diamminedichloroplatinum(II) (cisplatin) on nephrotoxicity in male Wistar rats was investigated. Animals received acyclovir (15 mg/kg body weight, s.c., three times per day for 5 days) or cisplatin (5 mg/kg body weight, i.p., one single injection) or a combination of both drugs. Acyclovir plasma levels were determined after one single acyclovir s.c. injection. Urines were monitored for volume, pH, osmolality and excretion of N-acetyl-beta-D-glucosaminidase (NAG), lysozyme and total protein. Concentrations of blood urea nitrogen and plasma creatinine were determined on day 6. Renal cortical slices were monitored to assess the accumulation of weak organic bases (tetraethylammonium) and acids (p-aminohippurate). Cisplatin induced a marked increase in the excretion of NAG, lysozyme and total protein and an increase in urine volume, plasma creatinine and blood urea nitrogen. Urine osmolality and accumulation of p-aminohippurate were depressed by cisplatin. Acyclovir treatment alone caused no significant symptoms of nephrotoxicity. Co-administration did not impair renal function more than cisplatin treatment alone, excepting a slight rise in lysozyme excretion on day 6. Short-term antiviral therapy with acyclovir, concomitant to cisplatin treatment, may bring, if at all, a slightly increased nephrotoxic risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyclovir / toxicity*
  • Animals
  • Body Weight / drug effects
  • Cisplatin / toxicity*
  • Creatinine / blood
  • Drug Synergism
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Male
  • Muramidase / urine
  • Organ Size / drug effects
  • Rats
  • Rats, Inbred Strains

Substances

  • Creatinine
  • Muramidase
  • Cisplatin
  • Acyclovir